What it is
SNAP-8 is a synthetic peptide of eight amino acids. On an ingredient label it appears under its INCI name, acetyl octapeptide-3, and occasionally as acetyl octapeptide-1.
It is sold to soften expression lines, and almost always positioned against an injected muscle relaxant — a topical alternative to a needle. The design story suppliers tell is that it mimics a fragment of SNAP-25, one of the proteins that docks vesicles at the nerve ending so that neurotransmitter can be released. The shorter peptide sold as Argireline carries the same story at six residues instead of eight, and SNAP-8 is marketed as the more potent of the two.
That is the claim. The record is smaller than the claim, and the interesting part is how much smaller.
The whole published record is two papers
PubMed holds 2 records naming this compound as of 2026-09-13:
- Annals of Dermatology, 2024;36(4):215–224 (PMID 39082657) — a dissolving microneedle patch study, 24 healthy subjects, active patch on one eye and placebo patch on the other, assessed over 28 days.
- Journal of Cosmetic Dermatology, 2020;19(2):328–337 (PMID 31134751) — bioactive peptides loaded on hyaluronic acid microneedle patches, a single-centre clinical study.
Both are genuine clinical work with human participants, published in peer-reviewed dermatology journals. Neither is a study of this peptide.
What the studies were actually comparing
In the 2024 paper the active patch is built from a hyaluronic acid backbone carrying acetyl octapeptide-3, L-ascorbic acid 2-glucoside and sodium cyclic lysophosphatidic acid. The placebo patch is hyaluronic acid and nothing else.
So the contrast is a patch with three actives against a patch with none. If the eye treated with the loaded patch does better, the result is consistent with the peptide working, with the vitamin C derivative working, with the lysophosphatidic acid working, with the microneedles themselves doing something, or with any combination of the four. The study was not designed to tell those apart, and it does not claim to. The 2020 paper has the same structure, announced in its own title: bioactive peptides, plural.
This is the check that costs one minute and is almost never done. A citation count tells you a compound appears in the literature. Reading what the compound was doing in each study — treatment, comparator, or one of several things held together — tells you whether any of it is evidence about the compound. Here, twice, the answer is no.
One further detail worth recording: Raphas Co. Ltd., the Korean company that manufactures the microneedle patches, appears as an author affiliation on both papers. That is ordinary in cosmetic science, and it is not a reason to discard either result. It does mean that the entire published literature on this ingredient comes from work connected to one patch maker.
The 92 that are not there
Search PubMed for the loose phrase acetyl octapeptide and it returns 92 records, a number that would make this compound look reasonably well studied.
The first fifteen of those by date include lentiviral vector promoters for a sulfatase gene, multi-O-GalNAcylated MUC5AC tandem repeats, the Pax5 C-terminal domain in B-cell development, peptaibol total synthesis, and angiotensin-converting-enzyme inhibitors. They match because they contain the word acetyl and the word octapeptide, in unrelated senses.
Search the ingredient names and the answer is two. The gap between 92 and 2 is not a subtlety of search syntax; it is the difference between a compound with a literature and a compound with two papers, and it resolves by reading the titles. This library has now found the same error class on several compounds, and it runs in both directions — a count that is too high because the search is loose, and a count that is too low because the trial was filed under a name the market does not use.
Where it stands
There is no approved medicine containing this peptide, and no application for one. Drugs@FDA returned nothing on 2026-09-13.
DailyMed holds two records, and they are worth naming precisely because they are easy to over-read: DERMA FIRM EYE, a cream listing acetyl tetrapeptide-5 and acetyl octapeptide-3, and DEEPAIR MICRO INTENSIVE MAGIC, a patch listing sodium hyaluronate, acetyl octapeptide-3 and madecassoside. These are product listings filed by their manufacturers in the database that also carries prescription drug labels. A listing records that a product exists and what is in it. It is not a review, an approval, or an endorsement of an ingredient — the same distinction this library has already had to draw for a bulk-powder registration filed by a chemical supplier on the VIP entry.
ClinicalTrials.gov held zero registrations on 2026-09-13.
How to read this entry
The honest summary is narrow. A microneedle patch containing this peptide and other actives improved eye wrinkles against an empty patch in a 24-person study, with no reported adverse effects. Everything beyond that sentence — that the peptide is responsible, that it works in a cream rather than on a needle, that eight residues beat six, that it does anything to a nerve — is either unmeasured or untested.
For which products contain it and at what concentrations, PeptideGlowJournal's SNAP-8 ingredient page covers the cosmetic market. This entry covers the compound. For the shorter peptide it is usually sold beside, see Argireline; for the other large name in cosmetic peptides, Matrixyl; and for the general question of what these molecules are, what peptides are.